Inmed Pharmaceuticals Stock Today
| INM Stock | USD 2.81 0.00 0.00% |
PerformanceVery Weak
| Odds Of DistressVery High
|
InMed Pharmaceuticals is selling at 2.81 as of the 21st of March 2025; that is No Change since the beginning of the trading day. The stock's lowest day price was 2.73. InMed Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of November 2020 | Category Healthcare | Classification Health Care |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. Inmed Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.21 M outstanding shares of which 35.88 K shares are currently shorted by investors with about 0.37 days to cover. More on InMed Pharmaceuticals
Moving together with InMed Stock
Moving against InMed Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
InMed Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | MIB Chem | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Independent News & Media PLC, Iron Mountain Incorporated] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInMed Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand InMed Pharmaceuticals' financial leverage. It provides some insight into what part of InMed Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
InMed Pharmaceuticals (INM) is traded on NASDAQ Exchange in USA. It is located in 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8 and employs 13 people. InMed Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a total capitalization of 3.36 M. InMed Pharmaceuticals runs under Biotechnology sector within Health Care industry. The entity has 1.21 M outstanding shares of which 35.88 K shares are currently shorted by investors with about 0.37 days to cover.
InMed Pharmaceuticals has about 9.35 M in cash with (6.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.98, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check InMed Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationRoughly 85.96 (percent) of InMed Pharmaceuticals outstanding shares are held by general public with 0.34 % owned by insiders and only 13.7 pct. by outside corporations.
Check InMed Ownership Details
InMed Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Xtx Topco Ltd | 2024-09-30 | 0.0 | |
| Hrt Financial Llc | 2024-12-31 | 0.0 | |
| Advisorshares Investments, Llc | 2024-12-31 | 38.5 K | |
| Ubs Group Ag | 2024-12-31 | 10.4 K | |
| Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 1.0 | |
| Allsquare Wealth Management Llc | 2024-12-31 | 1.0 | |
| Sabby Management Llc | 2024-09-30 | 0.0 | |
| Td Waterhouse Canada Inc | 2024-09-30 | 0.0 | |
| The Toronto-dominion Bank | 2024-09-30 | 0.0 | |
| Baader Bank Inc | 2024-12-31 | 0.0 | |
| Global Retirement Partners, Llc. | 2024-12-31 | 0.0 |
InMed Pharmaceuticals Historical Income Statement
InMed Stock Against Markets
InMed Pharmaceuticals Corporate Management
| Sazzad MSc | CoFounder | Profile | |
| Ado Muhammad | Consultant Affairs | Profile | |
| Colin Clancy | Director Relations | Profile | |
| Eric Hsu | Senior Development | Profile | |
| Jerry Griffin | Vice Marketing | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.42) | Revenue Per Share | Quarterly Revenue Growth (0.10) | Return On Assets | Return On Equity |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.